Insilico Medicine, a prominent company utilizing artificial intelligence (AI) for drug discovery, has unveiled a multi-year partnership with Servier, a global pharmaceutical provider. Together, they will focus on creating new treatments for cancer by using Insilico’s AI platform, Pharma.AI.
Under the deal, Insilico could receive up to USD 32 million in upfront and early payments. Insilico will lead the AI-driven discovery and development of potential drugs, while Servier will handle the clinical testing and commercialization.
Insilico has a lot of experience in using AI for cancer drug development. The company already has several promising cancer treatments, including the ISM6331 and ISM3412 drugs, both of which are currently in Phase I clinical trials. They also have other oncology programs that are in various stages of testing or licensing.
With its advanced AI and automation technologies, Insilico has greatly sped up the drug development process. While traditional drug discovery takes about 4.5 years, Insilico has been able to nominate 20 preclinical drug candidates in just 12 to 18 months per program.
Executive Statement
According to Christophe Thurieau, Executive Director Research at Servier, this collaboration underscores Servier's commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects their confidence in Insilico's internally developed and validated AI platform.
According to Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico Medicine, they are excited to see the collaboration, it is yet another strong acknowledgment of their AI capabilities and R&D expertise. As they deepen the integration of generative AI into every stage of the pharma value chain, they believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development.
